Transcranial magnetic stimulation for treatment of selected conditions
Transcranial magnetic stimulation (TMS) is a noninvasive technique used to stimulate areas of the brain associated with mood regulation and delivers intense magnetic pulses into the brain. There is a growing evidence base that TMS may be efficacious, with fewer or more tolerable side effects, and has led to growing interest in applying TMS to a broad set of conditions, most often those deemed treatment resistant.
Status: Decision completed
Why is TMS being reviewed?
This health technology assessment (HTA) reviews the efficacy, safety, and cost-effectiveness of TMS to assist the State of Washington's Health Technology Clinical Committee (HTCC) in determining coverage of TMS for the following selected behavioral health disorders: depression; anxiety disorders including generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD); posttraumatic stress disorder (PTSD); and addiction disorders including tobacco use disorder and substance use disorder (SUD).
Primary criteria ranking
- Safety = Low/Medium
- Efficacy = Medium/High
- Cost = Medium/High
Documentation
| Type | Materials |
|---|---|
| Assessment (2023) | |
| Related topics |
Assessment timeline
- Draft key questions published: July 8, 2022
- Public comment period: July 8 to July 22, 2022
- Final key questions published: August 23, 2022
- Draft report published: January 5, 2023
- Public comment period: January 5 to February 6, 2023
- Final report published: February 21, 2023
- HTCC public meeting: March 17, 2023
- Draft findings and decision published: March 31, 2023
- Public comment period: March 31 to April 14, 2023
- Final findings and decision published: June 29, 2023